National Vaccine
Information Center

Your Health. Your Family. Your Choice.

MedAlerts Home
Search Results

From the 9/17/2021 release of VAERS data:

Found 46 cases where Patient Died and Vaccination Date from '2020-01-01' to '2020-03-31'



Case Details

This is page 5 out of 5

Result pages: prev   1 2 3 4 5


VAERS ID: 895578 (history)  
Form: Version 2.0  
Age: 0.08  
Sex: Male  
Location: Foreign  
Vaccinated:2020-01-10
Onset:2020-01-10
   Days after vaccination:0
Submitted: 0000-00-00
Entered: 2020-11-09
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
PNC13: PNEUMO (PREVNAR13) / PFIZER/WYETH AH5529AJ6040 / UNK - / OT

Administered by: Other       Purchased by: ?
Symptoms: Death, Haemophagocytic lymphohistiocytosis, Pyrexia
SMQs:, Neuroleptic malignant syndrome (broad), Anticholinergic syndrome (broad), Drug reaction with eosinophilia and systemic symptoms syndrome (broad), Immune-mediated/autoimmune disorders (narrow)

Life Threatening? No
Birth Defect? No
Died? Yes
   Date died: 0000-00-00
Permanent Disability? No
Recovered? No
Office Visit? No
ER Visit? No
ER or Doctor Visit? No
Hospitalized? Yes, ? days
   Extended hospital stay? No
Previous Vaccinations:
Other Medications:
Current Illness:
Preexisting Conditions:
Allergies:
Diagnostic Lab Data: Test Date: 20200110; Test Name: axillary temperature; Result Unstructured Data: Test Result:more or equal to 38.6 Centigrade
CDC Split Type: CNPFIZER INC2020430188

Write-up: hemophagocytic syndrome; fever with axillary temperature more or equal to 38.6 centigrade; This is a spontaneous report from a contactable consumer. This is a report received from the Regulatory Authority. Regulatory authority report number was not provided. A 6-week-old male patient received pneumococcal 13-valent conjugate vaccine (diphtheria crm197 protein) (trade name unspecified, manufacturer: Pfizer; lot number: AH5529AJ6040), via intramuscular on 10Jan2020 at a single dose (reported as "0.5") for immunization. The patient medical history and concomitant medications were not reported. The patient experienced fever with axillary temperature more or equal to 38.6 centigrade and hemophagocytic syndrome on 10Jan2020 15:00. The patient was hospitalized due to the events. The patient died from the event on an unspecified date. It was not reported if autopsy was performed. The Adverse Event Following Immunization assessed the event as serious with a classification of a coincidental event. No follow-up attempts are possible. No further information is expected.; Reported Cause(s) of Death: hemophagocytic syndrome; fever with axillary temperature more or equal to 38.6 centigrade


VAERS ID: 1033467 (history)  
Form: Version 2.0  
Age: 73.0  
Sex: Female  
Location: Foreign  
Vaccinated:2020-03-23
Onset:2021-01-29
   Days after vaccination:312
Submitted: 0000-00-00
Entered: 2021-02-16
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
COVID19: COVID19 (COVID19 (UNKNOWN)) / UNKNOWN MANUFACTURER - / UNK - / OT
FLUX: INFLUENZA (SEASONAL) (NO BRAND NAME) / UNKNOWN MANUFACTURER - / UNK - / OT

Administered by: Other       Purchased by: ?
Symptoms: Acute respiratory failure, COVID-19, Cyanosis, Dyspnoea, Hyperhidrosis, Hypertension, Hypoxia, Pallor
SMQs:, Anaphylactic reaction (broad), Asthma/bronchospasm (broad), Neuroleptic malignant syndrome (broad), Shock-associated circulatory or cardiac conditions (excl torsade de pointes) (broad), Torsade de pointes, shock-associated conditions (broad), Hypovolaemic shock conditions (broad), Toxic-septic shock conditions (broad), Anaphylactic/anaphylactoid shock conditions (broad), Hypoglycaemic and neurogenic shock conditions (broad), Acute central respiratory depression (narrow), Pulmonary hypertension (broad), Hypertension (narrow), Cardiomyopathy (broad), Eosinophilic pneumonia (broad), Hypotonic-hyporesponsive episode (broad), Hypersensitivity (broad), Respiratory failure (narrow), Hypoglycaemia (broad), Infective pneumonia (broad), Opportunistic infections (broad), COVID-19 (narrow)

Life Threatening? No
Birth Defect? No
Died? Yes
   Date died: 2021-01-30
   Days after onset: 1
Permanent Disability? No
Recovered? No
Office Visit? No
ER Visit? No
ER or Doctor Visit? No
Hospitalized? Yes, ? days
   Extended hospital stay? No
Previous Vaccinations:
Other Medications:
Current Illness: Arterial hypertension
Preexisting Conditions: Medical History/Concurrent Conditions: Bedridden; Speech loss; Stroke
Allergies:
Diagnostic Lab Data: Test Name: covid 19; Test Result: Positive ; Result Unstructured Data: results and units were unknown
CDC Split Type: BRSA2021SA051803

Write-up: acute respiratory failure; cyanosis of extremities; dyspnoea; show profuse sweating; desaturation; pallor; covid 19; arterial hypertension; Initial information regarding this valid serious unsolicited case downloaded from regulatory authority database without narrative (level 2A), was received on 09-Feb-2021 from consumer/ non-health care professional via Health Authorities (Health Authority Reference Number BR-SA-SAC20210212001254). The following narrative is based on the information retrieved from all other accessible data. This case involves a 73-year old elderly female patient who experienced respiratory failure, cyanosis of extremities (cyanosis), dyspnoea, show profuse sweating (hyperhidrosis), desaturation (hypoxia), pallor, arterial hypertension (hypertension) and covid 19 (covid-19), while she received vaccine INFLUENZA VACCINE and COVID-19 VACCINE. Medical history included Stroke, Speech loss and was Bedridden. Past medical treatment(s), vaccination(s) and family history were not provided. At the time of the event, the patient had ongoing arterial hypertension. Concomitant medications were not reported. On 23-Mar-2020, the patient received INFLUENZA VACCINE [lot number: unknown and expiration date: unknown] at an unknown dose via unknown route in an unknown site of administration for prophylactic vaccination. On an unknown date, the patient received COVID-19 VACCINE [lot number: unknown and expiration date: unknown] at an unknown dose via unknown route in an unknown site of administration for prophylactic vaccination. On 29-Jan-2021, patient experienced acute respiratory failure, cyanosis of extremities (cyanosis), dyspnoea, show profuse sweating (hyperhidrosis), desaturation (hypoxia), pallor, arterial hypertension (hypertension) and covid 19 (covid-19), 10 months 6 days following the administration of suspect vaccine. The patient was hospitalized for these events (seriousness). Seriousness criteria was assessed as medically significant as per important medical event (IME) list for the event acute respiratory failure and Hypoxia, and COVID-19 as per reporter. It was not reported if the patient received a corrective treatment. Outcome of the events was fatal on 30-Jan-2021 for acute respiratory failure. There will be no information available regarding batch number in this case.; Sender''s Comments: This case concerns a 73-year-old female patient who experienced acute respiratory failure, cyanosis, dyspnoea, hyperhidrosis, hypoxia, pallor, hypertension and covid-19 after vaccination with company suspect INFLUENZA VACCINE and non-company suspect COVID-19 VACCINE. The time to onset was compatible with the events. Relevant laboratory test results included: COVID-19 - Positive [results and units were unknown] and Medical history included Stroke, Speech loss and was Bedridden. At the time of the event, the patient had ongoing arterial hypertension. Based upon the reported information, the role of an individual vaccine cannot be assessed.; Reported Cause(s) of Death: severe acute respiratory failure; cyanosis of extremities; dyspnoea; show profuse sweating; desaturation; pallor; arterial hypertension; COVID-19


VAERS ID: 1174594 (history)  
Form: Version 2.0  
Age:   
Sex: Male  
Location: Foreign  
Vaccinated:2020-03-04
Onset:2020-03-04
   Days after vaccination:0
Submitted: 0000-00-00
Entered: 2021-04-07
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
VARZOS: ZOSTER LIVE (ZOSTAVAX) / MERCK & CO. INC. S000095 / UNK - / -

Administered by: Unknown       Purchased by: ?
Symptoms: Death
SMQs:

Life Threatening? No
Birth Defect? No
Died? Yes
   Date died: 0000-00-00
Permanent Disability? No
Recovered? No
Office Visit? No
ER Visit? No
ER or Doctor Visit? No
Hospitalized? No
Previous Vaccinations:
Other Medications:
Current Illness:
Preexisting Conditions:
Allergies:
Diagnostic Lab Data:
CDC Split Type: GB0095075132103GBR004819

Write-up: She confirmed that it was a male patient, who died ?under one year'' after his vaccination; The vaccines have been administered to patients,; This spontaneous report was received from a nurse, referring to a 78-year-old patient of unknown gender. The patient''s pertinent medical history, concurrent conditions, previous drug reactions, or allergies were not reported. On 04-MAR-2020, the patient was vaccinated with an improperly stored zoster vaccine live (ZOSTAVAX) injection (strength, vaccination scheme, anatomical site of injection, and route of administration were not reported; lot number reported as S000095, expiration date was not reported, but upon internal validation was established as 31-MAY-2020) as prophylaxis (product storage error). This is one of several reports received from the same reporter. Follow up information has been received from the nurse on 30-MAR-2021. The patient''s gender was updated to male. On an unknown date (also reported as under one year after vaccination), the patient passed away. The causality assessment between the patient''s death and zoster vaccine live (ZOSTAVAX) was not reported.; Sender''s Comments: GB-009507513-2101GBR011501:


VAERS ID: 1210227 (history)  
Form: Version 2.0  
Age:   
Sex: Female  
Location: Foreign  
Vaccinated:2020-01-01
Onset:2020-01-01
   Days after vaccination:0
Submitted: 0000-00-00
Entered: 2021-04-15
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
COVID19: COVID19 (COVID19 (PFIZER-BIONTECH)) / PFIZER/BIONTECH EJ6796 / UNK - / OT

Administered by: Other       Purchased by: ?
Symptoms: Anaemia, Haematoma muscle, Off label use
SMQs:, Rhabdomyolysis/myopathy (broad), Haematopoietic erythropenia (broad), Haemorrhage terms (excl laboratory terms) (narrow)

Life Threatening? No
Birth Defect? No
Died? Yes
   Date died: 2021-01-12
   Days after onset: 377
Permanent Disability? No
Recovered? No
Office Visit? No
ER Visit? No
ER or Doctor Visit? No
Hospitalized? Yes, ? days
   Extended hospital stay? No
Previous Vaccinations:
Other Medications: Eliquis
Current Illness:
Preexisting Conditions: Medical History/Concurrent Conditions: Cardiovascular disease, unspecified; Chronic kidney disease
Allergies:
Diagnostic Lab Data:
CDC Split Type: ESPFIZER INC2021402001

Write-up: Hematoma muscle; Anemia; The patient received Apixaban at 2.5 mg/24h for atrial fibrillation; This is a spontaneous report from a contactable physician via regulatory authority (regulatory authority number: ES-AEMPS-798845), based on information received by Pfizer from a company (manufacturer control number: ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-031295) through regulatory authority, license party for apixaban (ELIQUIS). This case was received via HA (Reference number: ES-AEMPS-798845) on 29Mar2021 and was forwarded to regulatory authority on 29Mar2021. This spontaneous case was reported by a physician and describes the occurrence of HAEMATOMA MUSCLE (Hematoma muscle) and ANAEMIA (Anemia) in 86-year-old female patient who received apixaban (Eliquis) for Cerebrovascular accident prophylaxis. CO-SUSPECT PRODUCTS included Covid-19 Vaccine for COVID-19 immunization. Product or product use issues identified: OFF LABEL USE (The patient received Apixaban at 2.5 mg/24h for atrial fibrillation) on 01Jan2020. The patient''s past medical history included Cardiovascular disease, unspecified and Chronic kidney disease. On 01Jan2020, the patient started Eliquis (Oral), 2.5 milligram once a day. On 05Jan2021, the patient started Covid-19 Vaccine (Intramuscular). On 05Jan2021, the patient experienced HAEMATOMA MUSCLE (seriousness criterion hospitalization) and ANAEMIA (seriousness criterion hospitalization). Eliquis (Oral) was withdrawn on 05Jan2021. At the time of the report, HAEMATOMA MUSCLE and ANAEMIA was resolving. Therapy with COVID-19 vaccine and Apixaban was withdrawn on 05Jan2021. Causality was not provided for COVID-19 vaccine. The patient died due to cardiac failure and chronic kidney disease on 12Jan2021. For Eliquis (Oral), the reporter did not provide any causality assessments. Follow-up not performed, as case was downloaded from regulatory authority. Regulatory authority medical evaluation comment: This patient had muscle hematoma and anemia after therapy with apixaban. Based on the anticoagulant action of the suspect drug, its contributory role in these reported events are considered as possible. Causality Assessment: The events "Hematoma muscle, Anemia" were considered related to ELIQUIS by Company). The event "Off label dosing frequency" was considered unrelated to ELIQUIS by Company.; Sender''s Comments: Regulatory authority medical evaluation comment: This patient had muscle hematoma and anemia after therapy with apixaban. Based on the anticoagulant action of the suspect drug, its contributory role in these reported events are considered as possible.; Reported Cause(s) of Death: cardiac failure; chronic kidney disease


VAERS ID: 1304077 (history)  
Form: Version 2.0  
Age:   
Sex: Female  
Location: Foreign  
Vaccinated:2020-01-21
Onset:2021-04-22
   Days after vaccination:457
Submitted: 0000-00-00
Entered: 2021-05-10
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
COVID19: COVID19 (COVID19 (PFIZER-BIONTECH)) / PFIZER/BIONTECH EW4815 / 2 - / -

Administered by: Other       Purchased by: ?
Symptoms: Blood bicarbonate, Blood creatinine, Blood glucose, Blood glucose increased, Blood lactic acid, Blood potassium, Blood pressure increased, Blood pressure measurement, Blood sodium, Body temperature, Cerebral haemorrhage, Chest X-ray, Coma scale, Coma scale abnormal, Computerised tomogram, Eosinophil count, Haematocrit, Haemoglobin, Heart rate, International normalised ratio, International normalised ratio increased, Loss of consciousness, Lymphocyte count, Mean cell volume, Monocyte count, Neutrophil count, Oxygen saturation, PCO2, PO2, Platelet count, Platelet count decreased, Pneumonia aspiration, Prothrombin level, Prothrombin level increased, Red blood cell analysis, SARS-CoV-2 test, Scan brain, Vomiting, White blood cell count, pH body fluid
SMQs:, Torsade de pointes/QT prolongation (broad), Liver-related coagulation and bleeding disturbances (narrow), Acute pancreatitis (broad), Haematopoietic thrombocytopenia (narrow), Haemorrhage terms (excl laboratory terms) (narrow), Haemorrhage laboratory terms (broad), Hyperglycaemia/new onset diabetes mellitus (narrow), Neuroleptic malignant syndrome (broad), Systemic lupus erythematosus (broad), Anticholinergic syndrome (broad), Arrhythmia related investigations, signs and symptoms (broad), Haemorrhagic central nervous system vascular conditions (narrow), Noninfectious encephalitis (broad), Noninfectious encephalopathy/delirium (broad), Noninfectious meningitis (broad), Gastrointestinal nonspecific symptoms and therapeutic procedures (narrow), Hypertension (narrow), Hypotonic-hyporesponsive episode (broad), Generalised convulsive seizures following immunisation (broad), Drug reaction with eosinophilia and systemic symptoms syndrome (broad), Hypoglycaemia (broad), COVID-19 (broad)

Life Threatening? No
Birth Defect? No
Died? Yes
   Date died: 0000-00-00
Permanent Disability? No
Recovered? No
Office Visit? No
ER Visit? No
ER or Doctor Visit? No
Hospitalized? No
Previous Vaccinations:
Other Medications: BISOPROLOL
Current Illness:
Preexisting Conditions: Medical History/Concurrent Conditions: Cardiovascular disease, unspecified (Hypertension excluded); Iron deficiency; Type 2 diabetes mellitus
Allergies:
Diagnostic Lab Data: Test Name: HCO3; Result Unstructured Data: Test Result:26.9; Test Name: Creatinine; Test Result: 0.7 mg/dl; Test Name: Glucose; Test Result: 260 mg/dl; Test Date: 20210422; Test Name: Glucose; Test Result: 240 mg/dl; Test Name: Lactate ion; Result Unstructured Data: Test Result:2.4; Test Name: K; Result Unstructured Data: Test Result:4.0 mEq/l; Test Name: Blood pressure; Result Unstructured Data: Test Result:187/97 mmHg; Test Name: Sodium; Result Unstructured Data: Test Result:139 mEq/l; Test Name: temperature; Result Unstructured Data: Test Result:36.3 Centigrade; Test Name: Chest Rx; Result Unstructured Data: Test Result:possible bronchoaspiration; Test Date: 20210422; Test Name: Thorax X-ray; Result Unstructured Data: Test Result:No signs of acute cardiopulmonary decompensation.; Comments: In both lung bases, some ill-defined millimeter nodular images are identified that in the context could be secondary to occupation of a small airway by bronchoaspiration. No signs of acute cardiopulmonary decompensation.; Test Date: 20210422; Test Name: glasgow; Result Unstructured Data: Test Result:4; Test Name: CT; Result Unstructured Data: Test Result:massive intraventricular hemorrhage; Test Name: Eosinophils; Test Result: 0.1 %; Test Name: Hematocrit; Test Result: 41.6 %; Test Name: Hemoglobin; Result Unstructured Data: Test Result:14.1 g/dl; Test Name: Heart rate; Result Unstructured Data: Test Result:79; Comments: bpm; Test Date: 20210422; Test Name: INR; Result Unstructured Data: Test Result:3.8; Test Date: 20210422; Test Name: Lymphocytes; Test Result: 8.2 %; Test Name: MCV; Result Unstructured Data: Test Result:94.5; Comments: fL; Test Name: Monocytes; Test Result: 3.0 %; Test Name: Neutrophils; Test Result: 88.5 %; Test Name: Sat O2; Test Result: 95 %; Test Name: SatO2; Result Unstructured Data: Test Result:41.6; Test Name: pCO2; Result Unstructured Data: Test Result:51.0; Test Name: pH; Result Unstructured Data: Test Result:7.345; Test Name: Platelets; Result Unstructured Data: Test Result:133.0; Comments: 10e3 / uL; Test Date: 2018; Test Name: Platelets; Result Unstructured Data: Test Result:133.0; Comments: 10e3 / uL; Test Date: 2020; Test Name: Platelets; Result Unstructured Data: Test Result:150.0; Comments: 10e3 / uL; Test Date: 20210422; Test Name: Low platelets; Result Unstructured Data: Test Result:133000; Comments: Units:/uL; Test Name: PO2; Result Unstructured Data: Test Result:26.0; Test Name: Prothrombin Activity; Result Unstructured Data: Test Result:18.0; Test Name: Red blood cells; Result Unstructured Data: Test Result:4.4; Comments: 10e3 / uL; Test Date: 20210422; Test Name: COVID-19 PCR test; Test Result: Negative ; Test Date: 20210422; Test Name: Scan brain; Result Unstructured Data: Test Result:Extensive hemoventricle with hydrocephalus; Comments: Extensive hem ventricle with hydrocephalus and transependymal transudation; Test Name: Leukocytes; Result Unstructured Data: Test Result:9.4; Comments: 9.4 10e3 / uL
CDC Split Type: ESPFIZER INC2021491305

Write-up: Haemorrhage intracerebral; Unconscious; vomiting; possible broncho aspiration; Blood pressure was 187/97 mmHg; Glasgow 4.; Glucose: 260 mg / dL; INR(international normalized ratio): 3.8; Prothrombin Activity: 18.0; Low platelets: 133000/uL; This is a spontaneous report from a contactable physician downloaded from the Agency Regulatory Authority-WEB, regulatory authority number ES-AEMPS-842453. A 83-years-old female patient received BNT162B2 (COMIRNATY), dose 2 via an unspecified route of administration on 19Apr2021 (Batch/Lot Number: EW4815) as single dose for COVID-19 immunisation; acenocoumarol (SINTROM), oral from 21Jan2020 (Batch/Lot number was not reported) to an unspecified date, at 4 mg for atrial fibrillation. Medical history included PD of iron deficiency and type II diabetes mellitus September 2020. Reasons for the patient''s vaccination was Over 65 years of age, Cardiovascular disease (excluding HT(Hypertension)). Concomitant medication(s) included bisoprolol (BISOPROLOL) taken for an unspecified indication, start and stop date were not reported. The patient has Chronic treatment with Bisoprolol 2.5 1/2-0-0, Sintrom 4mg according to calendar. The patient previously received first dose of COMIRNATY (Lot number: ET7205) on 29Mar2021 for COVID-19 immunisation. On 22Apr2021, Patient who lived alone and had been found by a relative on the floor of her home with traces of vomiting around. BP(Blood pressure): 187/97 mmHg; Temperature 36.3 C; HR 79 bpm; Sat. O2 (%) 95; Unconscious. Glasgow 4. Summary of additional tests: Biochemistry Emergencies: Glucose: 260 mg / dL, Creatinine: 0.7 mg / dL, Sodium: 139 mEq / L, K+(Potassium): 4.0 mEq / L. Emergency blood count: Hemoglobin: 14.1 g / dL, Hematocrit: 41.6%, MCV(Mean corpuscular volume): 94.5 fL, Red blood cells: 4.4 10e3 / uL, Platelets: 133.0 10e3 / uL, Leukocytes: 9.4 10e3 / uL, Neutrophils: 88.5%, Lymphocytes: 8.2% , Monocytes: 3.0%, Eosinophils: 0.1%. Coagulation Emergencies: INR(international normalized ratio): 3.8, Prothrombin Activity: 18.0. Venous blood gases: pH: 7.345, pCO2(partial pressure of carbon dioxide): 51.0, PO2(partial pressure of oxygen): 26.0, HCO3(Bicarbonate): 26.9, SatO2(Oxygen saturation): 41.6, Lactate ion: 2.4, Image: CT(computed tomography) scan: massive intraventricular hemorrhage. Chest Rx(X/Ray): possible bronchoaspiration. Applied treatment: vitamin K. In analysis of 2018 platelets of 133.0 10e3 / uL and in 2020 150.010e3 / uL. In analysis of 2018, platelets of 133.0 10e3 / uL and in 2020, 150.010e3 / uL. On 22Apr2021, the patient had Glucose 240mg/dl, Thorax X-ray: In both lung bases, some ill-defined millimeter nodular images are identified that in the context could be secondary to occupation of a small airway by bronchoaspiration. No signs of acute cardiopulmonary decompensation, INR:3.8, lymphocytes: 8.2%, Low platelets: 133000/uL, COVID-19 PCR test was negative, Scan brain: Extensive hemoventricle with hydrocephalus and transependymal transudation. On an unknown date in 2021, the patient died. It is unknown if autopsy was done. No follow-up attempts are possible. No further information expected. Information about batch number already obtained.; Sender''s Comments: Based on temporal association, the causal relationship between BNT162B2 and the events cannot be excluded. The information available in this report is limited and does not allow a medically meaningful assessment. This case will be reassessed once additional information becomes available. The impact of this report on the benefit/risk profile of the Pfizer product is evaluated as part of Pfizer procedures for safety evaluation, including the review and analysis of aggregate data for adverse events. Any safety concern identified as part of this review, as well as any appropriate action in response, will be promptly notified to Regulatory Authorities, Ethics Committees, and Investigators, as appropriate; Reported Cause(s) of Death: Blood pressure was 187/97 mmHg; vomiting; Unconscious; Haemorrhage intracerebral; possible broncho aspiration; Glucose: 260 mg / dL; Glucose: 260 mg / dL; INR(international normalized ratio): 3.8; Prothrombin Activity: 18.0; Low platelets: 133000/uL


VAERS ID: 1584702 (history)  
Form: Version 2.0  
Age:   
Sex: Male  
Location: Foreign  
Vaccinated:2020-01-17
Onset:2021-06-26
   Days after vaccination:526
Submitted: 0000-00-00
Entered: 2021-08-19
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
COVID19: COVID19 (COVID19 (PFIZER-BIONTECH)) / PFIZER/BIONTECH FE2083 / 2 - / -

Administered by: Other       Purchased by: ?
Symptoms: Blood cholesterol, Blood pressure measurement, Chest pain, Electrocardiogram, Low density lipoprotein, Sudden cardiac death, Ultrasound scan
SMQs:, Torsade de pointes/QT prolongation (broad), Arrhythmia related investigations, signs and symptoms (narrow), Shock-associated circulatory or cardiac conditions (excl torsade de pointes) (narrow), Gastrointestinal nonspecific symptoms and therapeutic procedures (broad), Cardiomyopathy (broad)

Life Threatening? No
Birth Defect? No
Died? Yes
   Date died: 2021-08-02
   Days after onset: 37
Permanent Disability? No
Recovered? No
Office Visit? No
ER Visit? No
ER or Doctor Visit? No
Hospitalized? No
Previous Vaccinations:
Other Medications: DOLATRAMYL; PREGABALIN SANDOZ; MALFIN; CIPRAMIL [CITALOPRAM HYDROBROMIDE]; FUCICORT; IMOVANE; SUMATRIPTAN MYLAN
Current Illness: Chronic back pain
Preexisting Conditions: Medical History/Concurrent Conditions: Depression; Infected eczema; Neuropathic pain; Pain; Sleeplessness.
Allergies:
Diagnostic Lab Data: Test Date: 202001; Test Name: Cholesterol total; Result Unstructured Data: Test Result:5.7; Comments: unit not specified; Test Date: 202001; Test Name: Blood pressure; Result Unstructured Data: Test Result: normal; Test Date: 20210802; Test Name: EKG; Result Unstructured Data: Test Result: continuingly measured, unknown; Test Date: 20210802; Test Name: EKG; Result Unstructured Data: Test Result: ventricle fibrillation found, then asystole; Test Date: 202001; Test Name: LDL; Result Unstructured Data: Test Result: 3.7; Comments: unit not specified; Test Date: 20210802; Test Name: Ultrasound scan; Result Unstructured Data: Test Result: stagnant cordis.
CDC Split Type: DKPFIZER INC202101045522

Write-up: sudden cardiac death, found lifeless after doing hedge trimming; Retrosternal chest pain on/off since 2nd vaccination; This is a spontaneous report from a contactable physician downloaded from the Regulatory Authority-WEB, regulatory authority number DK-DKMA-WBS-0082510. A 58-years-old male patient received second dose of bnt162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE ,Lot Number: FE2083; Expiration Date: 31Oct2021) via an unspecified route of administration on 25Jun2021 as a dose 2 ,single for covid-19 immunisation, sumatriptan succinate (SUMATRIPTAN MYLAN), oral from 17Jan2020 (Batch/Lot Number: Unknown), at 100 mg as needed for migraine. Medical history included ongoing back pain, depression, pain, eczema infected, insomnia, neuralgia from an unknown date and unknown if ongoing. Concomitant medication(s) included tramadol hydrochloride taken for pain from 25Nov2015 to an unspecified stop date; pregabalin (PREGABALIN SANDOZ) taken for neuralgia from 18Feb2021 to an unspecified stop date; morphine sulphate taken for pain from 04May2017 to an unspecified stop date; citalopram hydrobromide taken for depression from 02Sep2019 to an unspecified stop date; betamethasone valerate, fusidic acid taken for eczema infected from 07Mar2016 to an unspecified stop date; zopiclone taken for insomnia from 24Jan2020 to an unspecified stop date. On 02Aug2021 the patient experienced sudden cardiac death, found lifeless after doing hedge trimming, on 26Jun2021 retrosternal chest pain on/off since 2nd vaccination. The patient was attempted treated with cardiopulmonary resuscitation when found lifeless. Upon arrival on the address. A detectable heart rhythm was found. The patient was given 5 direct current conversions, adrenaline and amiodaron i.o., without effect. The rhythm is primarily from ventricle fibrillation. The patient is transported with acute helicopter to a hospital and ventricle fibrillation is found using ultrasound. The patient was treated twice with direct current conversion and magnesium without effect, and the patient goes into asystole. The patient underwent lab tests and procedures which included blood cholesterol: 5.7 on Jan2020 unit not specified, blood pressure measurement: normal on Jan2020, low density lipoprotein: 3.7 on Jan2020 unit not specified. On 26Jun2021, the day after 2nd dose vaccination with Comirnaty, the patient developed Retrosternal chest pain (Retrosternal chest pain on/off since 2nd vaccination). Patient apparent to be a physical well and healthy and was not known to have any cardiovascular diseases or previous history with chest pain. The patient was attempted treated with cardiopulmonary resuscitation when found lifeless. Upon arrival on the address. A detectable heart rhythm was found. The patient was given 5 direct current conversions, adrenaline and amiodaron i.o., without effect. The rhythm was primarily from ventricle fibrillation. The patient was transported with acute helicopter to a hospital and ventricle fibrillation is found using ultrasound on 02Aug2021 which showed stagnant cordis. The patient was treated twice with direct current conversion and magnesium without effect. EKG continuingly measured, Ventricle fibrillation found and then patient gone to asystole. On 02Aug2021 the patient developed sudden cardiac death sudden cardiac death, found lifeless after doing hedge trimming). Physician had reported the death to the police and did not know if an autopsy will be performed. Respond from the Safety Authority awaits. Causality: The reporter states, that he is a summer substitute and has not seen the patient. All information in the report is from the patient''s electronic medical records. The reporter received information about the death of the patient and upon reading the patient''s medical records, the reporter started suspecting a possible relation between Comirnaty and the ADRs. The reporter also suspects Sumatriptan to be a possible suspected drug after reading the product resume However, nothing in the patient''s medical records suspects that the patient has reacted negatively to Sumatriptan before. There is no information weather the patient has experienced ADRs after the first dose vaccination with Comirnaty. No follow-up attempts possible. No further information expected.; Reported Cause(s) of Death: Sudden cardiac death


Result pages: prev   1 2 3 4 5

New Search

Link To This Search Result:

https://medalerts.org/vaersdb/findfield.php?EVENTS=ON&PAGENO=5&DIED=Yes&VAX_YEAR_LOW=2020&VAX_MONTH_LOW=01&VAX_YEAR_HIGH=2020&VAX_MONTH_HIGH=03


Copyright © 2021 National Vaccine Information Center. All rights reserved.
21525 Ridgetop Circle, Suite 100, Sterling, VA 20166